Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Panel OKs Free COVID-19 Vaccination for Ages 5-11, but No “Effort” Obligation Applied
February 14, 2022
- MHLW Panel to Review Bayer’s CKD Drug Finerenone Again on Feb. 25
February 14, 2022
- Pfizer’s Paxlovid Contraindicated with Many Medicines, Requires Careful Use
February 14, 2022
- Japan Approves Pfizer’s Paxlovid, Second Oral COVID-19 Pill
February 10, 2022
- LDP Health Committee to Review PMD Law Amendment Bill Mid-February
February 10, 2022
- Chuikyo Issues 2022 Reform Recommendation; Patch Prescription Limit Lowered to 63 Sheets
February 10, 2022
- Conditional OK Might Be an Option for KM Biologics Jab: Komeito Lawmaker
February 9, 2022
- MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
February 9, 2022
- MHLW Ordered Label Revisions for Emergency Contraceptive Levonorgestrel
February 8, 2022
- Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
- Japan to Speed Up Boosters to “1 Million Doses per Day” ASAP: PM
February 7, 2022
- Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication
February 7, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- FY2022 Drug Price Revision Rate at -6.69% on Pharma Spending Basis
February 4, 2022
- Pfizer’s COVID-19 Pill Up for PAFSC Review on Feb. 10
February 4, 2022
- 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
- Govt Panel Proposes Enhanced Pharma Supply Chain through Economic Security Bill
February 2, 2022
- MHLW Clarifies Position on Investigational Drug Info; No Generic Names Allowed on Companies’ Clinical Trial Websites
February 2, 2022
- DPO Opted Not to Apply 80% Pricing Rule for Vynmac for Clinical Benefits: Minutes
February 2, 2022
- MHLW OKs 115 More COVID-19 Vaccine Health Damage Claims
February 1, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…